ONCYOncolytics Biotech, Inc.

Oncolytics Biotech said preclinical data showed its experimental immunotherapy produced stronger anti-tumor effects in combination therapy, supporting future studies in pancreatic and colorectal cancers.

Oncolytics shares rise as pelareorep shows 19.5-month response durability and higher response rates in colorectal cancer study.read more...

Shares of Oncolytics Biotech Inc. (NASDAQ:ONCY - Get Free Report) have received an average rating of "Moderate Buy" from the five brokerages that are currently covering the firm, MarketBeat reports...

Oncolytics Biotech Inc. (NASDAQ:ONCY - Free Report) - Equities research analysts at HC Wainwright upped their Q1 2026 EPS estimates for Oncolytics Biotech in a research note issued on Friday, April 10th. HC Wainwright analyst P. Trucchio now anticipates that the company will earn ($0.03) per share f...

Oncolytics Biotech Inc. (NASDAQ:ONCY - Free Report) - Stock analysts at HC Wainwright issued their Q1 2027 EPS estimates for Oncolytics Biotech in a report released on Friday, April 10th. HC...

Oncolytics Biotech Inc. (NASDAQ:ONCY - Free Report) - Zacks Research issued their Q1 2026 earnings estimates for shares of Oncolytics Biotech in a note issued to investors on Tuesday, April 7th...

Oncolytics Biotech Inc. (NASDAQ:ONCY - Free Report) - Equities research analysts at Zacks Research issued their FY2026 earnings per share estimates for Oncolytics Biotech in a research note issued to...

Oncolytics Biotech Inc. (NASDAQ:ONCY - Get Free Report) has been given an average rating of "Moderate Buy" by the five research firms that are covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, two...

Wall Street Zen upgraded shares of Oncolytics Biotech from a "strong sell" rating to a "hold" rating in a research report on Saturday...